Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening?
Identifying novel bio markers in gastro intestinal disease is a promising method where a comprehensive analysis of the metabolome is performed. Metabolomics has evolved enormously in the past decade, paving a path in gastro intestinal disease research, especially diseases which lead to high morbidity and mortality. Metabolomics involves identifying metabolites such as anti-oxidants, and amino acids etc., which are screened in the urine, feces and tissue samples. Certain cases employ advanced tools like GC-MS, 1HNMR and GC-MS/SPME which reveal valuable information concerning disease severity and differentiation. In light of escalating health care costs and risky invasive procedures, metabolomics can be chosen as a safe yet precise method for screening diseases like ulcerative colitis, Crohns' disease, celiac disease, and gastro intestinal cancers. The present review focuses on major advancements in gastro intestinal metabolomics, giving attention to which parameters are assessed, and to recent changes in metabolite analysis..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Combinatorial chemistry & high throughput screening - 20(2017), 3, Seite 247-254 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rohit Gundamaraju [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1995399779 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1995399779 | ||
| 003 | DE-627 | ||
| 005 | 20230512181436.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170721 |
| 035 | |a (DE-627)OLC1995399779 | ||
| 035 | |a (DE-599)GBVOLC1995399779 | ||
| 035 | |a (PRQ)b1617-4bb796adef16fd74f6d2027d3932b19d126b8574ee68ba85607d4db21c50e3a70 | ||
| 035 | |a (KEY)0349000920170000020000300247metabolomicsasafunctionaltoolinscreeninggastrointe | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.42 |2 bkl | ||
| 100 | 0 | |a Rohit Gundamaraju |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Metabolomics as a Functional Tool in Screening Gastro Intestinal Diseases: Where are we in High Throughput Screening? |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Identifying novel bio markers in gastro intestinal disease is a promising method where a comprehensive analysis of the metabolome is performed. Metabolomics has evolved enormously in the past decade, paving a path in gastro intestinal disease research, especially diseases which lead to high morbidity and mortality. Metabolomics involves identifying metabolites such as anti-oxidants, and amino acids etc., which are screened in the urine, feces and tissue samples. Certain cases employ advanced tools like GC-MS, 1HNMR and GC-MS/SPME which reveal valuable information concerning disease severity and differentiation. In light of escalating health care costs and risky invasive procedures, metabolomics can be chosen as a safe yet precise method for screening diseases like ulcerative colitis, Crohns' disease, celiac disease, and gastro intestinal cancers. The present review focuses on major advancements in gastro intestinal metabolomics, giving attention to which parameters are assessed, and to recent changes in metabolite analysis. | ||
| 700 | 0 | |a Ravichandra Vemuri |4 oth | |
| 700 | 0 | |a Rajaraman Eri |4 oth | |
| 700 | 0 | |a Hamilton M. Ishiki |4 oth | |
| 700 | 0 | |a Ericsson Coy-Barrera |4 oth | |
| 700 | 0 | |a Nagendra Sastry Yarla |4 oth | |
| 700 | 0 | |a Sócrates Golzio dos Santos |4 oth | |
| 700 | 0 | |a Mateus Feitosa Alves |4 oth | |
| 700 | 0 | |a José Maria Barbosa Filho |4 oth | |
| 700 | 0 | |a Margareth F. F. M. Diniz |4 oth | |
| 700 | 0 | |a Marcus T. Scotti |4 oth | |
| 700 | 0 | |a Luciana Scotti |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Combinatorial chemistry & high throughput screening |d Hilversum [u.a.] : Bentham Science Publ., 1998 |g 20(2017), 3, Seite 247-254 |w (DE-627)33876982X |w (DE-600)2064785-2 |w (DE-576)415476674 |x 1386-2073 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2017 |g number:3 |g pages:247-254 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1386-2073&volume=20&issue=3&spage=247 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 936 | b | k | |a 44.42 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2017 |e 3 |h 247-254 | ||